Table 4 Dose coefficients for absorbed organ doses [mGy/MBq] and the effective dose [mSv/MBq] for adults administered with 2-[18F]FDG
From: A revised compartmental model for biokinetics and dosimetry of 2-[18F]FDG
Organ | Adult male (revised model) [mGy/MBq] | Adult female (revised model) [mGy/MBq] | Adult ICRP 128 [mGy/MBq] | Difference: adult male (revised model) versus ICRP 128 |
|---|---|---|---|---|
Adrenals | 1.4E−02 | 1.6E−02 | 1.2E−02 | + 13% |
Brain | 3.0E−02 | 3.3E−02 | 3.8E−02 | − 21% |
Breast | 7.6E−03 | 9.7E−03 | 8.8E−03 | − 13% |
Colon wall | 1.2E−02 | 1.5E−02 | 1.2E−02 | + 1% |
Endosteum (bone surface) | 1.0E−02 | 1.2E−02 | 1.1E−02 | − 7% |
Extrathoracic region | 7.6E−03 | 8.5E−03 | N/A | N/A |
Gallbladder wall | 1.1E−02 | 1.3E−02 | 1.3E−02 | − 14% |
Heart wall | 6.5E−02 | 8.4E−02 | 6.7E−02 | − 3% |
Kidneys | 2.0E−02 | 2.3E−02 | 1.7E−02 | + 16% |
Liver | 1.5E−02 | 1.8E−02 | 2.1E−02 | − 29% |
Lungs | 1.3E−02 | 1.7E−02 | 2.0E−02 | − 37% |
Lymphatic nodes | 1.3E−02 | 1.4E−02 | N/A | N/A |
Muscle | 8.3E−03 | 1.0E−02 | 1.0E−02 | − 17% |
Oesophagus | 1.5E−02 | 1.7E−02 | 1.2E−02 | + 23% |
Oral mucosa | 8.8E−03 | 9.9E−03 | N/A | N/A |
Ovariesa | N/A | 2.4E−02 | 1.4E−02 | + 71% |
Pancreas | 1.6E−02 | 1.8E−02 | 1.3E−02 | + 23% |
Prostate | 2.7E−02 | N/A | N/A | N/A |
Red (active) bone marrow | 1.5E−02 | 1.8E−02 | 1.1E−02 | + 33% |
Salivary glands | 7.8E−03 | 9.7E−03 | N/A | N/A |
Skin | 6.3E−03 | 7.7E−03 | 7.8E−03 | − 19% |
Small intestine wall | 1.3E−02 | 1.7E−02 | 1.2E−02 | + 8% |
Spleen | 1.4E−02 | 1.7E−02 | 1.1E−02 | + 31% |
Stomach wall | 1.2E−02 | 1.3E−02 | 1.1E−02 | + 10% |
Testes | 8.6E−03 | N/A | 1.1E−02 | − 22% |
Thymus | 9.8E−03 | 1.2E−02 | 1.2E−02 | − 18% |
Thyroid | 9.1E−03 | 1.1E−02 | 1.0E−02 | − 9% |
Urinary bladder wall | 7.5E−02 | 9.2E−02 | 1.3E−01 | − 43% |
Uterus/cervixa | N/A | 3.3E−02 | 1.8E−02 | + 82% |
Effective dose ICRP 60 (mSv/MBq) | 1.9E−02 | |||
Effective dose ICRP 103 (mSv/MBq) | 1.7E−02 |